Mankind Pharma FY26 revenue rises 17% to ₹14,278 crores
Published on: July 11, 2026, 9:24 p.m. | Source: scanx.trade
Mankind Pharma Limited has scheduled its 35th Annual General Meeting for August 4, 2026, via Video Conferencing to transact business including the adoption of financial statements and director re-appointments. The company reported a 17% year-on-year increase in revenue from operations to ₹14,278 crores for FY2025-26, while consolidated profit after tax stood at ₹1,938 crores. Operational highlights include the integration of the BSV acquisition, progress in the R&D pipeline, and a 190 bps increase in chronic portfolio share.
